• ADAM-17: a novel therapeutic target for triple negative breast cancer.

      McGowan, P M; Mullooly, M; Caiazza, F; Sukor, S; Madden, S F; Maguire, A A; Pierce, A; McDermott, E W; Crown, J; O'Donovan, N; et al. (2013-02)
      Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.
    • mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.

      Walsh, S; Flanagan, L; Quinn, C; Evoy, D; McDermott, E W; Pierce, A; Duffy, M J; UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland. (Elsevier, 2012-04)
      Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptors (ER), progesterone receptors (PR) and overexpression of HER2. Targeted therapy is currently unavailable for this subgroup of breast cancer patients. mTOR controls cancer cell growth, survival and invasion and is thus a potential target for the treatment of patients with TNBC. Using immunohistochemistry, mTOR and p-mTOR were measured in 89 TNBCs and 99 non-TNBCs. While mTOR expression was confined to tumor cell cytoplasm, p-mTOR staining was located in the nucleus, perinuclear area and in the cytoplasm. Potentially important, was our finding that nuclear p-mTOR was found more frequently in triple-negative than non triple-negative cancers (p < 0.001). These results suggest that mTOR may play a more important role in the progression of TNBC compared to non-TNBC. Based on these findings, we conclude that mTOR may be a new target for the treatment of triple-negative breast cancer.